If you work in the biotech industry, you might know the name Alex Denner. If not, his name probably doesn’t ring a bell.

A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical ...

The round, which included more than a dozen investment firms, should give the startup enough cash to get late-stage data for ...

In this article, we will be taking a look at the 15 best biotech stocks to buy according to billionaires. Although biotech ...

Congress did not reauthorize the rare pediatric disease priority review program at the end of 2024. Advocates say the ripple ...

The therapy joins another VMAT2 inhibitor, NBI-1065890, which is undergoing assessment by the company in Phase I trials.

Biosciences announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of investigational ...

Robert Lenz is leaving the brain drug developer to “pursue other interests.” Elsewhere, Atara is cutting half of its staff ...

Obesity and pharmacology experts are warning about hidden safety risks and efficacy issues for many types of medications in people with obesity.

Rusfertide met all primary and secondary endpoints in a Phase 3 trial for polycythemia vera, with strong efficacy and safety results, earning Protagonist $25 million.